GLOBAL LEADER

Cellect Biotechnology was founded in 2011 with a mission to become a global leader in the next generation of cellular therapies by developing innovative solutions for immune system regeneration.

INNOVATIVE SOLUTIONS

Achieving higher selectivity, greater specificity and decreased toxicity, Cellect envisions its products becoming an integral and essential part of Bone Marrow Transplantation (BMT), as well as integrated into many aspects of regenerative medicine.

ABOUT

OUR TECHNOLOGY

The Company’s platform technology is based on the game changing perception that stem-cells functional properties rather than appearance should be used to develop superior identification, selection and utilization of stem cells.

HEMATOPOIETIC STEM CELLS

Hematopoietic stem and progenitor cells (HSPC) are a small renewable pool of precursors that generate the immune and Hematopoietic systems throughout life
FIND OUT MORE

01

STEM CELL TRANSPLANTATION

Stem cell transplantation (SCT) is a medical procedure where stem cells reconstruct and replace damaged tissues and organs – a potential cure for a wide range of diseases and disorders.
FIND OUT MORE

02

GRAFT VERSUS HOST DISEASE

Graft versus Host disease (GvHD) is a common complication of allogeneic (non related) as well as Haploidentical (family member) stem cell transplantations
FIND OUT MORE

03

TECHNOLOGY PLATFORM

Cellect Biotechnology is based on a new concept of functional allocation, selection and use of stem cells.

PRECLINICAL DATA

Studies were performed to define the most relevant efector molecules, the concentrations and conditions for the murine studies.

STEM CELLS SELECTION KIT

An off the shelf medical device with a much shorter procedure and no special laboratory required that significantly reduces costs.

The CL10X replaces bespoke treatments with an off the shelf device

Procedure and hospitalization period of days instead of months.

Implement our technology in your existing laboratory environments

Our solution offers significant cost savings compared to existing treatments

Interested in our innovative technology?

BLOG

Latest News

For all the latest news and information about our company and our products, visit our blog.
25 Aug 2016

Cellect Biotechnology Ltd. to Present at 18th Annual Rodman & Renshaw Global Investment Conference on September 12, 2016

Kfar Saba, Israel – August 25, 2016 – Cellect Biotechnology Ltd. (Nasdaq: “APOP”, TASE: “APOP”), a developer of innovative technology which enables the functional selection of stem cells, today announced that Dr. Shai Yarkoni, Chief Executive Officer, will present a corporate overview at the 18th Annual Rodman & Renshaw Global Investment Conference, which is being […]

Read more
29 Jul 2016

Cellect Biotechnology Ltd. Announces Pricing of U.S. Initial Public Offering and NASDAQ Listing

Kfar Saba, Israel, July 29, 2016 – Cellect Biotechnology Ltd. (NASDAQ: APOP, APOPW; TASE: CLBD), a developer of innovative technology which enables the functional selection of stem cells, today announced the pricing of its initial public offering in the United States of 1,292,308 American Depository Shares (“ADSs”) and warrants to purchase up to 969,231 ADSs. […]

Read more

Interested in our innovative technology?

Contact Us